A Single Centre, Double-blind, Randomised Study To Investigate a Single Oral Dose of IMD-1041 in A Nasal Allergen Challenge Model

Trial Profile

A Single Centre, Double-blind, Randomised Study To Investigate a Single Oral Dose of IMD-1041 in A Nasal Allergen Challenge Model

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2012

At a glance

  • Drugs IMD 1041 (Primary)
  • Indications Grass pollen hypersensitivity; Seasonal allergic rhinitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Institute of Medicinal Molecular Design
  • Most Recent Events

    • 06 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top